Oddly, perhaps, the best performing stock in the first two weeks of the year is drug maker Merck & Co. Inc. (NYSE: MRK). The stock has added 5.89% year to date. Last Wednesday was a big day for the company, as three analysts lifted the …
New Jersey-based Merck & Co. Inc. MRK is a global research-driven pharmaceutical products company. Well known products in Merck’s portfolio include Remicade, Nasonex, Simponi, Vytorin and Zetia, Januvia and Janumet, Isentress, …
Shares of Bristol-Myers Squibb Company (BMY) declined as much as 3.5% Thursday after the global healthcare giant reported fourth quarter fiscal 2016 earnings results that missed Wall Street's profit estimates. A revenue beat during the …
Investors in Merck & Co., Inc. MRK need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 1, 2017 $65 Call had some of the highest implied volatility of all equity options today. What is …
If the stock closes at or above $55 at expiration this trade will return 2.13% or 7.87% (for comparison purposes only). MRK closed Jan 10, 2018's trading session at $57.29. In the past year, the stock has hit a 52-week low of $53.63 and 52 …
The stock topped all stock searches on google today. Merck & Co., Inc. (NYSE: MRK) closed at 36.88, up by 0.67(1.85%) yesterday. Merck has been making significant R&D investments in increasing the level of good cholesterol, which are …
Merck & Co. (MRK) announced late Friday that it withdrew its application for approval of Keytruda in Europe. Merck gapped open lower Monday morning and is now down 2.83 at $55.41. The stock has been pulling back from resistance at the …
Merck & Co., Inc. MRK will be reporting second-quarter 2017 earnings on Jul ... show that Merck is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 …
Mr. Kenneth C. Frazier is the Chairman of the Board, President and Chief Executive Officer of the Company. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company (2009 to 2010) and …
We expect Merck & Co., Inc. MRK to beat expectations when it reports third-quarter ... this quarter because it has the right combination of two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 …